脂必妥与洛伐他汀用于治疗高胆固醇血症的对比分析

目的：比较脂必妥与洛伐他汀治疗高胆固醇血症的疗效、安全性和经济性。方法：检索相关文献，对报道中符合要求的脂必妥临床试验结果进行Meta分析，并与洛伐他汀进行对比分析；同时采用专家评分法对脂必妥和洛伐他汀从六个方面进行总体评价。结果：Meta分析结果表明，脂必妥降低三酰甘油和升高高密度脂蛋白作用较洛伐他汀强，对老年患者的严重药物不良反应少，价格低，脂必妥与洛伐他汀的专家评分结果差异无显著性意义。结论：两种药物均为治疗高胆固醇血症的有效药物，脂必妥用于轻中度混合性血脂升高的老年患者较安全而且经济适用。

Comparison of zhibituo and lovastatin in the treatment of hyperlipidemia

Objective:To compare the efficacy, safety and economics of zhibituo and lovastatin in the treatment of hyperlipidemia. Methods:Searching medical references were done, The qualified results of clinical trials were Meta-analysed for evaluating the efficacy of zhibituo comparing with lovastatin. The characters of zhibituo and lovastatin were also compared through scoring by senior physicians. Results:The results of Meta-analysis showed that zhibituo had stronger effects on lowering TG and elevating HDL.It had less severe ADR for old people and cost less than lovastatin. The results of physicians-scoring records showed no significant difference between these two drugs. Conclusion:Zhibituo and lovastatin both are potential lipid-lowering agents. zhibituo is safer and more cost-effective for old people with mild to moderate elevated serum LDL level.